Extracellular Matrix Alterations in Patients With Paroxysmal and Persistent Atrial Fibrillation Biochemical Assessment of Collagen Type-I Turnover by Kallergis, Eleftherios M. et al.
R
fi
c
t
a
t
b
m
n
h
d
F
H
2
Journal of the American College of Cardiology Vol. 52, No. 3, 2008
© 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00
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Extracellular Matrix Alterations in Patients
With Paroxysmal and Persistent Atrial Fibrillation
Biochemical Assessment of Collagen Type-I Turnover
Eleftherios M. Kallergis, MD,* Emmanuel G. Manios, MD,* Emmanuel M. Kanoupakis, MD,*
Hercules E. Mavrakis, MD,* Dimitris A. Arfanakis, MD,* Niki E. Maliaraki, MD,†
Chrisovalantis E. Lathourakis, MD,* Gregory I. Chlouverakis, PHD,*
Panos E. Vardas, MD, PHD, FESC, FACC*
Crete, Greece
Objectives We investigated whether the serum markers of collagen turnover differed in various forms of atrial fibrillation
(AF) and in sinus rhythm (SR) in humans.
Background Structural alterations and fibrosis have been implicated in the generation and perpetuation of AF.
Methods Serum C-terminal propeptide of collagen type-I (CICP), C-terminal telopeptide of collagen type-I (CITP), matrix
metalloproteinase-1, and tissue inhibitor of matrix metalloproteinases-1 were measured as markers of collagen
synthesis and degradation in 70 patients with AF and 20 healthy control subjects in SR.
Results C-terminal propeptide of collagen type-I and CITP were significantly higher in AF patients than in control subjects
(91  27 ng/ml vs. 67  11 ng/ml, p  0.001 and 0.38  0.20 ng/ml vs. 0.25  0.08 ng/ml, p  0.001, re-
spectively). Persistent AF patients had higher levels of CICP (105  28 ng/ml vs. 80  21 ng/ml, p  0.001),
but not CITP, compared with those with paroxysmal AF. Patients with persistent AF had lower levels of matrix
metalloproteinase-1 but increased levels of tissue inhibitor of matrix metalloproteinases-1 compared with pa-
tients with paroxysmal AF (11.90  4.79 ng/ml vs. 14.98  6.28 ng/ml, p  0.03 and 155  45 ng/ml vs.
130  38 ng/ml, p  0.001, respectively). Tissue inhibitor of matrix metalloproteinases-1 levels were signifi-
cantly lower in control subjects compared with those in both paroxysmal and persistent AF patients (102  15
ng/ml vs. 130  38 ng/ml vs. 155  45 ng/ml, respectively, p  0.001).
Conclusions Serum markers of collagen type-I turnover differed significantly between patients with AF and SR. Furthermore,
these markers also differed significantly between paroxysmal and persistent AF patients, suggesting that the
intensity of the extracellular synthesis and degradation of collagen type-I may be related to the burden or type
of AF. (J Am Coll Cardiol 2008;52:211–5) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.03.045c
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tecent data from cardiac biopsies of patients with atrial
brillation (AF) have demonstrated a substantial increase in
ollagen deposition in the atria of humans with AF as opposed
o those in sinus rhythm (SR) (1–3). Preliminary experimental
nd clinical data suggest that biochemical markers of collagen
urnover correlate significantly with fibrosis in endomyocardial
iopsies in hypertensive patients (4). However, although such
arkers have been shown to differ between hypertensive and
ormotensive individuals, studies of their association with
ypertrophy or other echocardiographic parameters have pro-
uced inconsistent results (5,6).
rom the *Department of Cardiology and †Laboratory of Biochemistry, University
ospital of Heraklion, Crete, Greece.f
Manuscript received October 29, 2007; revised manuscript received February 13,
008, accepted March 18, 2008.Collagen type-I is the major collagenous product of
ardiac fibroblasts (7). We assessed the amount of fibrosis in
atients with paroxysmal or persistent lone AF using serum
nalysis of peptides derived from the tissue synthesis (C-
erminal propeptide of collagen type-I [CICP]) and degra-
ation (C-terminal telopeptide of collagen type-I [CITP])
f collagen type-I (4). Enzymes that control collagen type-I
urnover, specifically matrix metalloproteinase (MMP)-1
nd tissue inhibitor of matrix metalloproteinases (TIMP)-1,
ere also measured (8).
ethods
he ethics committee of our institution approved the study,
hich conformed to the principles outlined in the Declara-
ion of Helsinki. Informed written consent was obtained
rom all subjects.
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Fibrosis and AF July 15, 2008:211–5The study population con-
sisted of 70 ambulatory patients
(age 24 to 78 years) who suffered
from lone AF, defined as AF
without clinical or echocardio-
graphic evidence of cardiopul-
monary disease, including hyper-
tension. The arrhythmia was
considered paroxysmal when it
was self-terminating in 24 h
and persistent when it was doc-
umented on sequential 12-lead
electrocardiograms, without any
intervening periods of SR, for at
least 3 months preceding enroll-
ment. Patients with persistent
AF had been referred to our
department for electrical cardio-
version; none had undergone
uch a procedure before. No patient had permanent AF,
efined as sustained arrhythmia despite cardioversion.
wenty healthy subjects in SR with no history of atrial
rrhythmias served as a control group.
Exclusion criteria were conditions associated with ele-
ated serum concentrations of myocardial or tissue fibrosis
arkers, such as liver disease, renal impairment, pulmonary
brosis, extensive wounds, metabolic bone disease, malig-
ancy, connective tissue disorders, chronic inflammatory
isease, and recent infection or surgery. Patients who were
ver 80 years old or had a pacemaker/implantable
ardioverter-defibrillator were also excluded.
Using a case-control study design, serological markers of
ollagen type-I turnover, echocardiographic maximal left
trial (LA) diameter, and left ventricular ejection fraction
LVEF) were compared in patients and control subjects.
iltiazem and beta-blockers were allowed for ventricular
ate control, and all AF patients received the indicated
ntithrombotic treatment.
All patients were in AF at the time of blood sampling.
lood samples were obtained at the time of the clinical
tudies and were immediately placed on ice and centrifuged
ithin 1 h. Specimens were stored at 80°C until analysis.
Serum TIMP-1 and MMP-1 levels were assayed by
nzyme-linked immunoadsorbent assay with commercially
vailable kits (Human Biotrack enzyme-linked immunoad-
orbent assay system, Amersham Biosciences, Piscataway,
ew Jersey). C-terminal propeptide of collagen type-I levels
ere determined by a sandwich enzyme immunoassay with
commercially available kit (enzyme immunoassay, Metra
ICP, Quidel, San Diego, California), while CITP was
easured using the Elecsys -CrossLaps/serum assay
Roche Diagnostics, Mannheim, Germany). Measurements
ere performed by personnel blinded to the patients’ clinical
etails. The intra- and interassay coefficients of variation of
Abbreviations
and Acronyms
AF  atrial fibrillation
CICP  C-terminal
propeptide of collagen
type-I
CITP  C-terminal
telopeptide of collagen
type-I
LA  left atrial
LVEF  left ventricular
ejection fraction
MMP  matrix
metalloproteinase
SR  sinus rhythm
TIMP  tissue inhibitor of
matrix metalloproteinasell assays were8% and10%, respectively, in our laboratory. wtatistical analysis. Summary descriptive statistics for con-
inuous parameters are presented as mean  SD. Categor-
cal variables were compared among the persistent, parox-
smal AF, and control groups using the chi-square test.
ne-way analysis of variance was used to test whether these
groups differed with respect to various continuous param-
ters of interest. Where findings were significant, post-hoc
ukey tests were performed to pinpoint differences. If the
omogeneity of variance assumption was violated, the non-
arametric Kruskal-Wallis test was used instead. Stepwise
ogistic regression analysis was used to assess whether age,
ender, LA, and fibrosis markers were independently asso-
iated with AF. Age, LA, and fibrosis markers were treated
s continuous variables in the model. The thresholds for
ntry into and removal from the model were 5% and 10%,
espectively. Associations between continuous variables of
nterest were assessed with correlation and linear regression
echniques. Values of p  0.05 were considered statistically
ignificant.
esults
atients. The baseline clinical and demographic features of
he study population are shown in Table 1. Thirty-two
atients had persistent and 38 paroxysmal AF. There were
o significant differences in gender (p  0.40) or age (p 
.058) between the AF groups. Control subjects were
ounger than AF patients (p 0.001), but were comparable
n terms of gender distribution. Patients with persistent AF
ad lower LVEF (p  0.038) and a larger LA (p  0.001)
ompared with paroxysmal AF patients.
erum markers of collagen turnover. The findings are
ummarized in Table 1. Both CICP and CITP levels were
ignificantly higher in persistent AF patients than in control
ubjects (p  0.016). Persistent AF patients also had higher
ICP levels compared with those with paroxysmal AF (p
.001), whereas there was no significant difference in CITP
evels (p  0.57) (Table 1, Figs. 1 and 2).
Patients with persistent AF had lower levels of MMP-1
p  0.026) but higher levels of TIMP-1 (p  0.013)
ompared with patients with paroxysmal AF (Table 1,
igs. 3 and 4). Tissue inhibitor of matrix metalloproteinases-1
evels were significantly lower (p  0.001) in control subjects
ompared with both paroxysmal and persistent AF patients
Fig. 4). Plasma MMP-1 levels did not differ significantly (p
.20) between persistent AF patients and control subjects
Fig. 3).
Finally, in all AF patients taken together, there was a
ositive correlation between both CICP and TIMP levels
nd LA dimension (r  0.635, p  0.001 and r  0.563,
 0.001, respectively) (Fig. 5), while there was a weak,
nverse relation between CICP and TIMP levels and LVEF
r  0.234, p  0.05 and r  0.278, p  0.020,
espectively). A positive correlation was also observed be-
ween MMP-1 levels and LVEF (r  0.30, p  0.012)
hile there was an inverse relation between MMP-1 levels
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July 15, 2008:211–5 Fibrosis and AFnd LA dimension (r  0.615, p  0.001). Logistic
egression analysis showed that, among age, gender, LA and
ollagen markers, TIMP-1, MMP-1, age, and CICP were
ndependently associated with AF (Table 2).
iscussion
atients initially presenting with paroxysmal AF often
rogress to persistent and eventually develop permanent
F. Although the exact pathophysiological mechanisms are
oorly understood, persistence of AF is thought to result
rom atrial remodeling (9,10). However, pure electrical
emodeling cannot explain the development of sustained AF
10,11). Atrial fibrosis, a factor with a slower time course,
ould be involved (3,12,13).
In this study we demonstrated an elevation in CICP and
ITP in the AF cohort taken as a whole compared with
Baseline Characteristics and Serum Markers ofin Patients With Persistent or Paroxysmal AF an
Table 1 Baseline Characteristics and Serumin Patients With Persistent or Paro
Persistent AF (n  32) Paroxys
Age (yrs) 65.34 13.31 6
Gender (M/F) 23/9
LVEF (%) 56.25 9.41 6
LA (mm) 44.37 4.62 3
BMI (kg/m2) 27.12 1.71 2
SBP (mm Hg) 138.59 12.52 13
DBP (mm Hg) 83.91 4.35 8
CICP (ng/ml) 105.06 27.57 7
CITP (ng/ml) 0.40 0.21
MMP-1 (ng/ml) 11.90 4.789 1
TIMP-1 (ng/ml) 154.90 44.91 12
Values are expressed as mean  SD. Post-hoc analysis showed that
subjects and persistent atrial fibrillation (AF) patients; 2) C-terminal p
significantly compared with both paroxysmal and control subjects; 3
differed significantly compared with both paroxysmal and persistent A
between persistent and paroxysmal AF patients; and 5) tissue inhib
intergroup comparisons.
BMI  body mass index; DBP  diastolic blood pressure; LVEF 
rhythm.
CICP
(ng/ml)
Controls Persistent AF Paroxysmal AF
30
60
90
120
150
180
Figure 1 Comparative Levels of Serum Concentration of CICP
C-terminal propeptide of collagen type-I (CICP) showed a gradual increase from
control subjects to paroxysmal and then to persistent atrial fibrillation (AF)
patients as shown in this box plot.hose in SR. Interestingly, persistent AF patients had the
ighest serum concentrations of CICP, whereas there was
o difference in CITP levels between patients with persis-
ent and paroxysmal AF. Thus, CICP demonstrated a
radual increase from control subjects to paroxysmal and
hen to persistent AF, but CITP did not, suggesting that
he intensity of the extracellular degradation of collagen
ype-I was insufficient to compensate for its increased
ynthesis, resulting in augmented fibrosis in patients with
ersistent AF.
Furthermore, in patients with persistent AF, MMP-1
evels were decreased, whereas TIMP-1 levels were in-
reased compared with paroxysmal AF patients. Levels of
IMP-1 were also higher in paroxysmal AF patients than in
ontrol subjects. In addition, control subjects had lower
evels of MMP-1 than paroxysmal AF patients but higher
gen Type-I Turnoveralthy Control Subj cts in SR
kers of Collagen Type-I Turnover
al AF and Healthy Control Subjects in SR
F (n  38) Control Subjects (n  20) p Value
12.37 56.75 5.21 0.025
1 12/8 0.621
4.42 60.00 4.58 0.227
3.67 37.15 3.54 0.001
1.44 26.95 1.39 0.919
11.90 131.75 10.03 0.079
4.34 83.75 4.55 0.633
21.23 67.3 11.05 0.001
0.19 0.25 0.08 0.016
6.28 12.63 1.21 0.033
37.92 102.10 15.13 0.001
e and left atrial diameter (LA) differed significantly between control
ide of collagen type-I (CICP) levels in persistent AF patients differed
inal telopeptide of collagen type-I (CITP) levels in control subjects
nts; 4) matrix metalloproteinase (MMP)-1 levels differed significantly
matrix metalloproteinase (TIMP)-1 levels differed significantly in all
tricular ejection fraction; SBP  systolic blood pressure; SR  sinus
CITP
(ng/ml)
0.20
0.40
0.60
0.80
Controls Persistent AF Paroxysmal AF
Figure 2 Box Plot of Serum Concentrations of CITP
C-terminal telopeptide of collagen type-I (CITP) in control subjects differed sig-
nificantly compared with that in both paroxysmal and persistent atrial fibrillation
(AF) patients.Collad He
Mar
xysm
mal A
1.79
27/1
0.13
7.23
7.02
8.55
4.74
9.84
0.37
4.98
9.75
: 1) ag
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Fibrosis and AF July 15, 2008:211–5evels than persistent AF patients (although the differences
id not reach statistical significance). That seems paradox-
cal, but it could be the result of the activation manner of
MP-1, which depends on the nature of the stimulus and
iffers in the setting of acute or chronic stimulation (14).
hus, short-lasting paroxysmal AF could result acutely in
ressure or volume overload, activating the MMP-1 system,
hich then becomes compromised with the prolongation
nd stabilization of the stimulus.
Another interesting finding was that both CICP and
IMP levels positively correlated with LA diameter and
nversely related to LVEF, whereas AF patients with a
arger LA and a smaller LVEF, probably as a result of a
onger arrhythmia duration, had lower MMP-1 levels.
Since our study included patients with lone AF only, we
an speculate that the aforementioned alterations were
Paroxysmal AFPersistent AFControls
30
25
20
15
10
5
0
MMP1
(ng/ml)
Figure 3 Intergroup Serum Concentrations of MMP-1
This box plot depicts matrix metalloproteinase (MMP)-1 levels that differed sig-
nificantly between persistent and paroxysmal atrial fibrillation (AF) patients.
TIMP1
(ng/ml)
50
100
150
200
250
300
Controls Persistent AF Paroxysmal AF
Figure 4 Box Plot Depiction of the
Differences in Levels of Serum TIMP-1
Tissue inhibitor of matrix metalloproteinase (TIMP)-1
levels differed significantly in all intergroup comparisons. AF  atrial fibrillation.Cttributable to the arrhythmia itself, and not to the presence
r absence of any confounding factor, with a progressive
ncrease in fibrosis from paroxysmal to persistent AF. In
ddition, the augmented fibrosis, especially in patients with
he persistent form of AF, could further suggest that if
ollagen modification plays a causal role, this relates to both
he initiation and the maintenance of AF.
tudy limitations and clinical implications. Serum mark-
rs of collagen turnover are not heart specific. In addition,
e did not support our findings with atrial tissue biopsy data
r coronary sinus sampling. However, we made strenuous
fforts to exclude subjects with conditions associated with
brosis.
Despite our efforts to match control subjects with AF
atients, the latter were older. However, collagen markers
iffered significantly between patients with persistent and
aroxysmal AF, despite the lack of any significant difference
n age, suggesting that age differences did not influence the
nterpretation of our results.
Serial measurements of collagen indexes after SR resto-
ation to evaluate the potential temporal alterations of
ollagen turnover are not available, although these data
ould undoubtedly have been a valuable addition to our
tudy and could have reinforced our findings.
52 03 53 04 54 05 55 06
LA (mm)
180
150
120
90
60
30
CICP
(ng/ml)
Persistent AF
Paroxysmal AF
Figure 5 Direct Correlation Between Serum Concentrations
of CICP and LA Diameter Dimensions
In all AF patients taken together, there was a positive correlation between CICP
and left atrial diameter (LA) dimension (r  0.635, p  0.001). Abbreviations
as in Figure 1.
ndependent Predictors of AF Accordingo Stepwise Logistic Regression Analysis
Table 2 Independent Predictors of AF Accordingto Stepwise Logistic Regression Analysis
Variable Odds Ratio 95% CI p Value
TIMP-1 1.17 1.06–1.28 0.002
MMP-1 1.77 1.28–2.46 0.001
Age 1.17 1.05–1.32 0.005
CICP 1.06 1.004–1.13 0.037I  confidence interval; other abbreviations as in Table 1.
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July 15, 2008:211–5 Fibrosis and AFFinally, the small patient sample size does not allow
ajor conclusions regarding the relationship between sys-
emic fibrosis and AF.
Given these limitations, this is the first study to estimate
he relationship between AF burden and serum markers of
ollagen type-I synthesis and degradation, demonstrating a
otential role for these markers in AF evaluation.
onclusions
erum markers of collagen type-I turnover may provide a
oninvasive method of documenting and monitoring both
he extent and the mechanisms of myocardial fibrosis in AF
atients and of evaluating pharmacological measures de-
igned to treat this arrhythmia. However, further investiga-
ion and randomized trials are needed to elucidate the exact
ole of fibrosis in AF and to evaluate the clinical importance
nd value of biochemical monitoring of collagen turnover in
his clinical setting. Although cardiac biopsy is the gold
tandard for documenting and monitoring myocardial fibro-
is, noninvasive methods offer a particularly attractive alter-
ative that could have a broader application.
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